★ America V2AuditLine ALPHA

AuditLine › HHS OIG › Centers for Medicare and Medicaid Services

HHS OIG recommendation 22-E-BL-027.01

CMS should encourage Part D plans to increase access to and use of the authorized generic versions of Epclusa and Harvoni, within the authorities…

Open UnimplementedThe publisher's status, as reported by HHS Office of Inspector General in the file read . Open for 4.3 years since it was issued.

The recommendation, in the publisher's words

CMS should encourage Part D plans to increase access to and use of the authorized generic versions of Epclusa and Harvoni, within the authorities granted under statute.
Responsible agency
Centers for Medicare and Medicaid Services
Issued
August 9, 2022
Report
Part D Plan Preference for Higher-Cost Hepatitis C Drugs Led to Higher Medicare and Beneficiary Spending (OEI-BL-21-00200) · find it at HHS OIG
Kind of report
Evaluation
Agency response
Concur (as recorded by the publisher)
Last update received
October 26, 2026
Next update expected
December 16, 2026 (publisher's date)
Publisher topics
Financial Stewardship, Prescription Drug

“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.

Dated history

  1. Issued by HHS OIG. (publisher's date)
  2. First recorded by AuditLine. (start of AuditLine's own history for this record)

Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.

Other recommendations from this report

1 more, of which 0 are open in the publisher's file.

Source

Open this report in HHS OIG's tracker This publisher's records (CSV)

Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows, SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.